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Bayesian variable selection for high
dimensional predictors and self-reported
outcomes
Xiangdong Gu1, Mahlet G Tadesse2, Andrea S Foulkes3, Yunsheng Ma4 and Raji Balasubramanian1*
Abstract
Background: The onset of silent diseases such as type 2 diabetes is often registered through self-report in large
prospective cohorts. Self-reported outcomes are cost-effective; however, they are subject to error. Diagnosis of silent
events may also occur through the use of imperfect laboratory-based diagnostic tests. In this paper, we describe an
approach for variable selection in high dimensional datasets for settings in which the outcome is observed with error.
Methods: We adapt the spike and slab Bayesian Variable Selection approach in the context of error-prone, self-
reported outcomes. The performance of the proposed approach is studied through simulation studies. An illustrative
application is included using data from the Women’s Health Initiative SNP Health Association Resource, which includes
extensive genotypic (>900,000 SNPs) and phenotypic data on 9,873 African American and Hispanic American women.
Results: Simulation studies show improved sensitivity of our proposed method when compared to a naive approach
that ignores error in the self-reported outcomes. Application of the proposed method resulted in discovery of several
single nucleotide polymorphisms (SNPs) that are associated with risk of type 2 diabetes in a dataset of 9,873 African
American and Hispanic participants in the Women’s Health Initiative. There was little overlap among the top ranking
SNPs associated with type 2 diabetes risk between the racial groups, adding support to previous observations in the
literature of disease associated genetic loci that are often not generalizable across race/ethnicity populations. The
adapted Bayesian variable selection algorithm is implemented in R. The source code for the simulations are available
in the Supplement.
Conclusions: Variable selection accuracy is reduced when the outcome is ascertained by error-prone self-reports. For
this setting, our proposed algorithm has improved variable selection performance when compared to approaches
that neglect to account for the error-prone nature of self-reports.
Keywords: Bayesian variable selection, Self-reports, High dimensional data
Background
The time to a silent event in several clinical settings
can only be assessed through sequentially administered
diagnostic tests. For example, diabetes can be detected
by measuring levels of fasting blood glucose or glycosy-
lated hemoglobin levels (HbA1c). Although gold standard
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diagnostic tests are often available, the associated cost is
prohibitive in large epidemiological studies which often
recruit hundreds of thousands participants. Instead, dis-
ease incidence is often ascertained through less expen-
sive but error-prone procedures such as self-report. One
example is the Women’s Health Initiative (WHI), which
enrolled 161,808 postmenopausal women aged 50-79
years at 40 clinical centers across the U.S. from 1993-1998
with ongoing follow-up [1]. Due to cost considerations,
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate
credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were
made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless
indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your
intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative
Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made
available in this article, unless otherwise stated in a credit line to the data.
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prevalent and incident type 2 diabetes is ascertained by
self-reported questionnaires at each annual visit. In this
paper, we propose and apply a Bayesian variable selection
(BVS) approach for variable selection in high dimensional
datasets while simultaneously accounting for the error-
prone nature of self-reported outcomes. We apply the
proposed methods to discover single nucleotide polymor-
phisms (SNPs) associated with type 2 diabetes risk in the
WHI Clinical Trial and Observational Study SNP Health
Association Resource (SHARe), which includes extensive
genotypic (>900,000 SNPs) and phenotypic data on 9,873
African American and Hispanic American women.The
proposed methods equally apply when a silent outcome
is ascertained through laboratory-based diagnostic proce-
dures that are subject to misclassification.
When a time-to-event outcome is ascertained by a per-
fect diagnostic test that is administered at pre-specified
time points during the course of follow up, the outcome
is interval-censored. In this context, methods to estimate
the survival distribution and assess covariate effects have
been developed [2, 3]. However, when an error-prone
diagnostic procedure such as a self-report is used instead,
standard methods for interval censored outcomes lead to
bias. Previous work in this area include methods for mod-
eling error-prone outcomes with application to studies in
HIV, HPV and STD [4–7]. A formal likelihood frame-
work was developed to estimate the distribution of the
time-to-event of interest in the presence of error-prone
laboratory-based diagnostic tests, in the context of pedi-
atric HIV clinical trials [5]. Also in the context of pediatric
HIV studies, the discrete proportional hazard model was
extended to incorporate mis-measured outcomes and also
covariates [7]. In related work, generalized Cox models
were considered in settings involving time-to-event out-
comes with incomplete event adjudication [8–10]. Other
related work includes that proposed in the context of HPV
studies [6], where the authors accommodate misclassifi-
cation by incorporating ideas of binary generalized linear
models with outcomes subject to misclassification [11]. A
formal likelihood framework was proposed to accommo-
date sequentially administered, error-prone self-reports
or laboratory based diagnostic tests for modeling the
association of a targeted set of covariates with the time-
to-event outcome of interest [12]. While a rich literature
exists to handle estimation and hypothesis testing in the
presence of error-prone survival outcomes, none of these
approaches can be applied directly to variable selection in
high-dimensional data, in which the number of features
(p) far exceeds the number of subjects (n). In this set-
ting, standard likelihood based estimation approaches are
intractable.
The BVSmethod has been previously proposed for vari-
able selection in high dimensional datasets [13, 14]. The
Bayesian model proceeds by assigning a mixture prior
distribution to the regression coefficients (β) correspond-
ing to the high dimensional predictors, for example - a
mixture of a point mass at 0 and a uniform distribution
[13], a mixture of two normal distributions centered at
0 but with distinct variances [14]. The estimated pos-
terior probabilities of the latent binary indicators for
inclusion in the model is used for variable selection. Sev-
eral papers have applied this approach for discovering a
sparse feature set associated with an outcome in high-
dimensional microarray data for various settings. Previous
works include models for binary outcomes [15], multi-
category responses [16], and censored outcomes [17].
Notably, the use of the BVS method in large-scale set-
tings such as genome-wide association studies (GWAS)
was successfully demonstrated [18]. The BVS approach
has also been extended to in application to clustered data
to simultaneously discover group structure and identify
discriminating variables [19–21]. One advantage of the
BVS approach when compared to other variable selection
methods is that it can be naturally extended to incorporate
external information such as biological pathway member-
ship [22, 23]. A comprehensive review of BVS algorithms
can be found in the literature [24]. Improvements to and
novel applications of the BVS procedure continues to be
an active area of research [25–28].
In this paper, we incorporate a BVS approach into
a likelihood-based model proposed by Gu, X. et al.
(2015). This allows us to conduct variable selection in
high dimensional data while accounting for the imper-
fect observation of a time-to-event outcome. Through
simulation studies, we illustrate the impact of ignoring
error in the outcome on variable selection and com-
pare the performance of the BVS spike-and-slab prior
with that of our proposed algorithm. We apply the
BVS approach to discover SNPs associated with inci-
dent type 2 diabetes in a dataset of 9,873 African
American and Hispanic American women enrolled in
the WHI.
The organization of this paper is as follows: In the
“Methods” section, we present notation and the form
of the likelihood function that accommodates error in
self-reported outcomes. We incorporate this likelihood
into the BVS algorithm, to handle high-dimensional
datasets. We conduct simulation studies to compare the
variable selection performance of different approaches
for high dimensional datasets arising from GWAS and
metabolomic studies. We apply our proposed meth-
ods for the discovery of single nucleotide polymor-
phisms (SNPs) associated with type 2 diabetes risk in
the WHI Clinical Trial and Observational Study SNP
Health Association Resource (SHARe), among African
American and Hispanic American women. Lastly, we
discuss the findings of this study and highlight future
directions.
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Methods
In this section, we introduce notation, present the form of
the likelihood function to accommodate error-prone, self-
reported outcomes that has been previously described
[12] and integrate with a BVS approach for variable selec-
tion.
Notation, likelihood function
Let X refer to the random variable denoting the unob-
served time-to-event for an individual, with associ-
ated survival, density and hazard functions denoted by
S(x), f (x) and λ(x), for x ≥ 0. The time origin is set to
0, corresponding to the baseline visit at which all subjects
enrolled in the study are assumed to be event-free. This
implies that Pr(X > 0) = 1.
Without loss of generality, we set X = ∞ when the
event of interest does not occur. Let N denote the num-
ber of subjects and ni denote the number of visits for the
ith subject during the follow-up period. At each visit, we
assume that a subject would self-report their disease sta-
tus as either positive or negative. For example, at each
semi-annual (WHI-CT) or annual contact (WHI-OS), all
participants were asked, “Since the date given on the front
of this form, has a doctor prescribed any of the following
pills or treatments?” Choices included “pills for diabetes”
and “insulin shots for diabetes”. Thus, incident treated dia-
betes was ascertained, and was defined as a self-report
of a new physician diagnosis of diabetes treated with oral
drugs or insulin.
Let τ1, · · · , τJ denote the distinct, ordered visit times in
the dataset among N subjects, where 0 = τ0 < τ1 < ... <
τJ < τJ+1 = ∞. Thus, the time axis can be divided into
J + 1 disjoint intervals, [0, τ1) , [τ1, τ2) , · · · ,
[
τJ ,∞
)
. Let Z
denote the P × 1 vector of covariates with corresponding
P × 1 vector of regression coefficients denoted by β . To
incorporate the effect of covariates, we assume the pro-
portional hazards (PH) model, λ (x|Z = z) = λ0(x)ez′β ,
or equivalently, S (x|Z = z) = S0(x)ez
′β . Thus, the log-
likelihood function for a random sample ofN subjects can
be expressed as:
l (θ ,β) =
N∑
i=1
log
⎛
⎜
⎜
⎝
J+1∑
j=1
Dij
⎛
⎝
j+1∑
k=j
θk
⎞
⎠
ez
′
iβ
⎞
⎟
⎟
⎠ , (1)
where θj = Pr
(
τj−1 < X ≤ τj
)
and where
∑J+1
j=1 θj = 1.
The elements Dij of the matrix D are functions of the
observed data including the visit times, the corresponding
self-reported results, and the constants ϕ0,ϕ1 that cor-
respond to the specificity and sensitivity of self-reports,
respectively. The details of the derivation were originally
reported in a previous publication [12] and have been
included in Section 1 of the Supplement.
When P << N and assuming that ϕ0,ϕ1 are
known, the maximum likelihood estimates of the
unknown parameters β1, · · · ,βP, θ1, · · · , θJ can
be obtained by numerical maximization of the
log-likelihood function in Eq. (1), subject to the con-
straints that
∑J+1
j=1 θj = 1 and θj > 0. Statistical
inference regarding the parameters of interest(
β1, · · · ,βP, θ1, · · · , θJ+1
)
can be made by using asymp-
totic properties of the maximum likelihood estimators
[29]. For settings in which P > N , a Bayesian approach
incorporating a spike and slab variable selection
procedure is described below.
Bayesian variable selection (BVS)
In this section, we adapt the spike and slab BVS approach
in the context of error-prone, self-reported outcomes. We
introduce a latent vector γ = (γp, 1 ≤ p ≤ P
)
, where
each γp is an indicator variable denoting whether the
pth covariate is included
(
γp = 1
)
or not
(
γp = 0
)
in the
model. The BVS analysis proceeds via MCMCmethods to
estimate the posterior distribution of γ . With this latent
variable formulation for variable selection, the log likeli-
hood function in Eq. (1) is a function of the parameters
θ1, · · · , θJ ,β , γ and is denoted l (θ ,β , γ ). We assume the
following hierarchical structure of the prior distributions
corresponding to the unknown parameters in the model:
θ ∼ Dirichlet(1)
βp | γp ∼ γpN(0, b2) + (1 − γp)δ0
γp | ω ∼ Bernoulli(ω)
ω ∼ Beta(w1,w2)
where δ0 is the Dirac function corresponding to a point
mass at 0 and where b,w1,w2 are treated as known hyper-
parameters.
By treating the interval probabilities θ as nuisance
parameters, we propose the followingMetropolis-Hasting
algorithm. At iteration t, we let the indices t − 1 and ∗
denote the current and proposed values of the parameters,
respectively.
1 Initialization: Set ω(0) to a randomly generated value
from Beta(w1,w2) distribution. Set γ (0) = 0 and
β(0) = 0. Optimize the log-likelihood function in
Eq. (1) with respect to θ by fixing β = β(0), and then
set θ (0) to equal the optimized value for θ .
2 Update selected variable and associated regression
coefficient: Select a covariate p ∈ (1, · · · ,P) at
random and let the proposed value γ ∗p = 1 − γ t−1p .
(a) If γ ∗p = 0, the corresponding regression
coefficient β∗p is set to 0. If γ ∗p = 1, the
proposed regression coefficient β∗p is sampled
from N
(
0, b2
)
distribution.
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(b) Optimize the log-likelihood function in Eq. (1)
with respect to θ by fixing β = β∗, denote the
optimized value to be θ∗. The optimized value
θ∗ is used as the proposed value for θ .
(c) Accept the proposed values
(
γ ∗p ,β∗p , θ∗
)
with
probabilitymin
(
e
, 1
)
where:

 = l (θ∗,β∗) − l
(
θ (t−1),β(t−1)
)
+
(
2γ ∗p − 1
)
log
(
ω(t−1)
1 − ω(t−1)
)
See Section 2 of the Supplement for details
regarding the derivation of 
.
3 Update regression coefficients and interval
probabilities: For each included covariate, update the
coefficient with a user defined probability pmain, for
example 0.30. If a main effect βp is chosen for update,
(a) Let the proposed value, β∗p , be a random
sample from the distribution N
(
β
(t−1)
p , b2
)
.
(b) Optimize the log-likelihood function in
Eq. (1) with respect to θ by fixing β = β∗,
where we denote the optimized value to be
θ∗. The optimized value θ∗ is used as the
proposed value for θ .
(c) Accept the proposed values
(
β∗p , θ∗
)
with
probabilitymin
(
e
, 1
)
where

 = l (θ∗,β∗) − l
(
θ (t−1),β(t−1)
)
+
(
β
(t−1)
p
)2 −
(
β∗p
)2
2b2
See Section 2 of the Supplement for details
regarding the derivation of 
.
4 Update ω: Using Gibbs sampling, update ω by
generating a sample from
Beta
(
w1 + Kγ ,w2 + P − Kγ
)
, where Kγ is the
number of main effects selected.
After the burn-in period, the covariates are ranked from
most to least important by their inclusion probabilities
based on the posterior distribution of γp.
Results
Simulation studies
We report results from simulation studies to evaluate the
performance of the proposed BVS algorithm in the pres-
ence of outcomes subject to error, under various parame-
ter settings. First, we consider a high dimensional dataset
in which each feature is a random variable with three lev-
els, reflecting the two possible homozygous (AA, aa) and
the single heterozygous (Aa) combination of alleles of a
SNP. In Section 3.2 of the Supplement, we consider a high
dimensional dataset in which each feature is a continuous
random variable, scaled to have mean 0 and unit variance.
The results presented here are averages of 1,000 sim-
ulated datasets, where each dataset included n = 100
subjects and P = 100 covariates. To mimic real data
settings, the 100 × 100 design matrix was obtained by
random sampling of a subset of 100 covariates for 100 par-
ticipants from the WHI Clinical Trial and Observational
Study SHARe (described below) and a metabolomics
study of cardiovascular disease (see Section 3.2. of the
Supplement). The design matrix was standardized before
simulation.
Results from error-prone self-reports for each subject
were simulated assuming four pre-scheduled visit times
per subject over 8 years of follow up, with no missed
visits. The distribution of true event times in the refer-
ence group (i.e. Z = 0) was assumed to be exponential
with baseline hazard denoted by λ0. The value of λ0 was
determined by fixing the corresponding cumulative inci-
dence rate (CIR) in the reference group to equal CIR =
10% or30%, over the 8-year study duration. The true event
time for each subject in the study was simulated from
an exponential distribution, where the hazard function
(λ) was determined through the PH model
(
λ = λ0eβZ
)
.
In each dataset, five out of 100 covariates were ran-
domly sampled as true associations with the outcome,
with a corresponding coefficient β = 1.0 (or, hazard
ratio of eβ ≈ 2.7) in the PH model. The regression
coefficients for the remaining 95 covariates in the PH
model were set to 0. For each subject, an error-prone self-
report (positive or negative) at each visit was simulated
from a Bernoulli distribution. At each visit, the probabil-
ity of a positive self-report was governed by the sensitivity
(ϕ1) if the visit time is after the true event time or the
complement of the specificity (ϕ0) if the visit time pre-
cedes the true event time. The values of (ϕ1,ϕ0) were
varied between [(1, 1), (1, 0.9), (0.75, 1), (0.61, 0.995)]. We
note that the sensitivity and specificity values (0.61, 0.995)
correspond to the properties of diabetes self-reports in the
WHI [30].
For each parameter setting, we compared the variable
selection performance of the following three strategies:
(1) Random survival forests assuming no error in self-
report [31]; (2) the proposed BVS algorithm assuming
no error in the self-report (ϕ1 = ϕ0 = 1); and (3) the
proposed BVS accounting for the imperfect nature of self-
reports. Our rationale for selecting these algorithms for
comparison include evaluating the: (1) performance of the
proposed BVS approach when compared to a distinct,
yet multivariable, non-parametric, tree-based ensemble
approach such as the Random Forests; and (2) potential
increase in variable selection accuracy when accounting
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for error in self-reports through the proposed BVS
approach.
1 Random survival forests (RSF): The algorithm
implemented in the randomForestSRC R package
[32] was applied to each dataset by defining the
time-to-event outcome as the time from baseline
(origin) to the time of the first positive self-report
(observed event) or the time of last observation
(censored observation). In particular, this results in
no difference in the handling of the two study designs
(“No missed visits” versus “NTFP”) . The Random
survival forests was implemented using the function
rfsrc in the package with default parameter setting,
e.g. there are 1,000 trees in the forest. The 100
covariates were ranked by the variable importance
metric output by the algorithm. The computing time
for a single 100 × 100 dataset on a Macbook Pro
2017 is about 2 seconds.
2 Proposed BVS assuming no error in self-reports(
BVSperfect
)
: This analysis was based on the proposed
BVS algorithm by setting ϕ1 = ϕ0 = 1. Note that in
this case, we only consider self-reports up to the first
positive report since negative self-reports that follow
a positive self-report have zero probability. The
MCMC algorithm was run up to 100,000 iterations
and the first 20,000 iterations were discarded as
burn-in. We set the values of the hyper-parameters
governing the prior distributions to the following:
b = 1.0,w1 = 5,w2 = 100. The 100 covariates were
ranked based on the posterior distribution of γ . The
computing time for a single 100 × 100 dataset on a
Macbook Pro 2017 is about 3 minutes.
3 Proposed BVS algorithm (BVSe): This analysis was
based on the proposed BVS algorithm by setting
ϕ1,ϕ0 to equal the values assumed in the data
generation process. This algorithm is implemented in
two ways: (1) Self-reports collected at all
pre-scheduled visits are included in the analysis
(referred to as “NMISS”); (2) Self-reports following
the first positive are discarded (referred to as “No
Test after First Positive or NTFP”). The MCMC
algorithm was run up to 100,000 iterations and the
first 20,000 iterations were discarded as burn-in. We
set the values of the hyperparameters governing the
prior distributions to the following:
b = 1.0,w1 = 5,w2 = 100. The computing time for a
single 100 × 100 dataset on a Macbook Pro 2017 is
about 3 minutes.
The R code for implementing the simulations
described in this Section has been included in
Section 4 of the Supplement. Model diagnostics of
the convergence of the MCMC chain and run length
control indicated that the choice of 100,000
iterations with a burn-in of 20,000 was justified (See
Section 3.1 in the Supplement).
The 100 × 100 design matrix for this simulation study
was randomly selected from the existing GWAS data
from the WHI Clinical Trial and Observational Study
SHARe, which includes extensive genotypic (> 900K
SNPs) and phenotypic data for 12,007 African American
and Hispanic American women. All missing genotypes
were imputed to be homozygous for the major allele “AA”.
Among the 100 SNPs selected in the design matrix for the
simulation, 74 had minor allele frequency (MAF) between
0 and 0.35 and the remaining 26 SNPs had MAF between
0.35 and 0.5. Each SNP was incorporated into the PH
model as a numeric covariate that was generated by cod-
ing genotype “AA” as 0, genotype “Aa” as 1, and “aa” as
2. In this model, the homozygous major allele (AA) cat-
egory serves as the reference group and the homozygous
‘aa’ category has twice the effect on outcome as the het-
erozygous ‘Aa’ category [33]. We note that this implies the
assumption of a linear effect across the ordered genotype
categories. While relaxing this assumption is straightfor-
ward from a modeling perspective, it would result in a
significant increase in computational complexity.
Figure 1 in the Supplement presents the posterior distri-
bution of γ for the 100 SNPs from a single representative
simulation. Here, the data generating mechanism for the
time-to-event outcome and self-reports was based on the
first five SNPs, each with corresponding regression coef-
ficient β = 0.7 in the PH model. The results were based
on ϕ1 = 0.61,ϕ0 = 0.995, a 30% rate of cumulative inci-
dence in the reference group, and assuming that there
were no missed visits. We observed that true associations
(SNPs 1-5) had significantly higher posterior probabilities
of inclusion when compared to the average correspond-
ing value for those SNPs that were not associated with
outcome.
Table 1 shows the proportion of simulated datasets
in which a SNP that is associated with the outcome
was found as ranking among the top five SNPs by
the posterior probability of inclusion - results are aver-
aged over the five SNPs with true associations with
the outcome. In all settings with the exception of one
(CIR = 0.1,ϕ1 = 1,ϕ0 = 0.9), the BVS and BVSe algo-
rithms perform better than RSF. When self-reports after
the first positive are excluded from analysis (NTFP), both
BVS and BVSe have comparable performance indicating
that the performance loss due to assuming incorrect sen-
sitivity and specificity values is negligible when test results
are discarded. However, when self-reports at all visit times
are included in analysis (“NMISS”), and when specificity
(ϕ0) is less than perfect, BVSe results in a significantly
higher probability of discovering true associations when
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Table 1 Probability of ranking among the top five SNPs by posterior probability of inclusion, for SNPs that are associated with
outcome. CIR denotes the cumulative incidence rate in the reference group, RSF denotes Random Survival Forests, BVSperfect denotes
the proposed BVS algorithm assuming perfect self-reports and BVSe denotes the proposed BVS procedure. NTFP denotes a study
design setting in which all self-reports following the first positive result are discarded and NMISS denotes the setting where there are
no missed visits
CIR sensitivity (ϕ1) specificity (ϕ0) RSF BVSperfect BVSe BVSe
NTFP NMISS
0.1 1 1 0.70(±0.01) 0.87(±0.01) 0.87(±0.01) 0.87(±0.01)
0.1 1 0.9 0.41(±0.01) 0.34(±0.01) 0.30(±0.01) 0.81(±0.01)
0.1 0.75 1 0.68(±0.01) 0.81(±0.01) 0.84(±0.01) 0.84(±0.01)
0.1 0.61 0.995 0.63(±0.01) 0.69(±0.01) 0.74(±0.01) 0.75(±0.01)
0.3 1 1 0.80(±0.01) 0.98(±0.01) 0.98(±0.01) 0.98(±0.01)
0.3 1 0.9 0.58(±0.01) 0.63(±0.01) 0.68(±0.01) 0.97(±0.01)
0.3 0.75 1 0.78(±0.01) 0.90(±0.01) 0.95(±0.01) 0.95(±0.01)
0.3 0.61 0.995 0.74(±0.01) 0.82(±0.01) 0.88(±0.01) 0.88(±0.01)
compared to BVS. For example, when CIR= 0.1, ϕ1 =
1.00, ϕ0 = 0.90, the probability of a SNP ranking among
the top five by BVSe under NMISS is 0.81 (±0.01) as com-
pared to 0.34 (±0.01) and 0.41 (±0.01) by BVS (assuming
perfect self-reports) and RSF, respectively. The false pos-
itive rates were comparable across algorithms for each
simulation setting.
Similar results were observed for the setting where
the features were continuous measurements, representing
data observed in metabolomic studies (Section 3.2 of the
Supplement).
Application
The proposed methods were applied to data from the
WHI Clinical Trial and Observational Study SHARe, to
identify SNPs associated with risk of incident type 2 dia-
betes mellitus. The dataset includes extensive genotypic
(909,622 SNPs) and phenotypic information on 12,008
African American and Hispanic American women. After
excluding participants who self-reported diabetes at base-
line, the analysis was restricted to 9,873 participants.
Prevalent diabetes at baseline and incident diabetes
were assessed through self-reported questionnaires in the
WHI. At baseline and at each annual visit, every partici-
pant was asked whether she had ever received a physician
diagnosis of and/or treatment for diabetes when not preg-
nant since the time of the last self-report/visit. Using
data from a WHI sub-study [30], estimates of sensitiv-
ity, specificity, and baseline negative predictive value of
self-reported diabetes outcomes were obtained by com-
paring self-reported outcomes to fasting glucose levels
and medication data. A participant was considered to be
truly diabetic if she had either taken anti-diabetic med-
ication and/or had a fasting glucose level ≥ 126mg/dL.
By using a subset of 5485 participants, with informa-
tion at baseline on diabetes self-reports, fasting glucose
levels and medication inventory, we estimated that self-
reports have a sensitivity (ϕ1) of 0.61 and a specificity
(ϕ0) of 0.995 [30]. These parameter values are used in our
analysis.
After excluding participants with self-reported diabetes
at baseline, the remaining subsets of 6,704 African Amer-
ican and 3,169 Hispanic American women were analyzed
independently. The results presented here are based on
follow up until 2013. The average follow up from base-
line was 11.6 years, with a maximum follow up of 16 years
- during this period, 21.2% of the African American and
18.5% of the Hispanic American women self-reported a
new diagnosis of diabetes.
The data pre-processing procedures resulted in 300,000
SNPs being included in the statistical analysis (Section 5
of the Supplement, Supplementary Figs. 2-3). Results from
the proposed BVS algorithm (BVSe) are compared to the
BVS algorithm assuming perfect self-reports (BVSperfect)
and to two SNP-by-SNP approaches, including a model
based on the likelihood in Eq. (1) (icensmis) [34] and
the Cox proportional hazards (PH) model. Details regard-
ing data pre-processing and the statistical models are
presented in Section 5 of the Supplement.
Figures 4-5 in the Supplement show bar plots of the
posterior probability of inclusion from the proposed algo-
rithm (BVSe) for the 300,000 SNPs included in each
analysis in the African American and Hispanic American
datasets, respectively. Since the dimensionality reduction
procedure was carried out within each dataset, not all
SNPs entered the BVSe analysis in both datasets. SNPs
that were found to rank among the top 10 most impor-
tant by at least one of the aforementioned analyses in the
datasets of African American women and Hispanic Amer-
ican women are shown in Tables 2 and 3, respectively.
Each SNP is annotated with its host gene (if known) and
its upstream and downstream genes. In both populations,
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Table 2 Rankings of individual SNPs in the WHI Clinical Trial and Observational Study SHARe among African American women in the
WHI (n = 6704). Results from the following analyses are reported: (1) The proposed BVS approach (BVSe); (2) BVS assuming perfect
tests
(
BVSperfect
)
; (3) univariate (SNP by SNP) analysis assuming a Cox PH model; and (4) univariate analysis adjusting for error in
self-report (icensmis). Each analysis simultaneously adjusted for the top two principal components to account for population
stratification. SNPs are ordered from most (rank= 1) to least important (rank > 1000) with regard to their association with time to
incident type 2 diabetes. Ranks > 1000 are denoted by −
BVSe BVSperfect Cox PH icensmis rs Intron Upstream Downstream
Rank Rank Rank Rank Number
1 2 1 1 rs2805434 RYR2
2 - 15 10 rs5946729 SHOX, CRLF2
3 - 28 20 rs10126793 PDK3 SUPT20HL1
4 - 3 3 rs10054129 RXFP3, ADAMTS12
5 - 22 16 rs7523871 RNU5F-1 LOC101929689, LYPLAL1
6 - - - rs6795523 IGSF11
7 - - - rs149091 ANKRD55 LOC102467147
8 - 81 69 rs10820848 LOC101927847 UNQ6494
9 - - - rs10950835 SP4 RPL23P8
10 - - - rs2714365 CHST9 CDH2
34 - 9 9 rs17693218 LYZL1 C10orf126
- - 2 2 rs2805429 RYR2
- - 5 5 rs7737188 RXFP3, ADAMTS12
- - 8 7 rs16917265 INIP, SNX30
- - 6 6 rs4144636 ASTN2
- - 7 8 rs12247963 FAM188A
- - 4 4 rs15958
- - 10 17 rs1959083 LINC00520, RPL13AP3
- 1 13 19 rs6573059 LINC00520, RPL13AP3
the rankings by the proposed BVSe algorithm differed
significantly from the rankings by BVS assuming perfect
self-reports and from each of the univariate (SNP by SNP)
analyses (Tables 2-3), underscoring the value in utilizing a
broad set of analytical approaches for variable selection in
high dimensional datasets. The BVS algorithm assuming
perfect self-reports identified only 2 SNPs in the African
American dataset and one SNP in the Hispanic American
dataset, with non-zero posterior probability of inclusion.
Interestingly, none of the SNPs discovered among the
top 10 (by at least one approach) in the African Ameri-
can dataset overlapped with the corresponding set in the
Hispanic American subcohort.
In the dataset of African American women, a total of 19
SNPs were identified in the top 10 by at least one of the
four strategies, while simultaneously adjusting for popu-
lation stratification (Table 2). SNP rs2805434 was ranked
within the top 2 ranks by all four analysis approaches.
The host gene RYR2 has been implicated in insulin secre-
tion in previous studies [35]. RYR2 is host to another
SNP (rs2805429) identified as second most important by
both univariate approaches in this population. rs2805434
was removed from the analysis dataset due to the pre-
processing procedures in the Hispanic American women.
Another finding with support in the literature is
that of SNP rs10126793 - its upstream gene PDK3
or pyruvate dehydrogenase kinase 3 is in the class
of PDK isoenzymes that have been shown to be
strong therapeutic targets for preventing and treat-
ing metabolic diseases [36]. rs10126793 had a weak
association with type 2 diabetes risk in the Hispanic
American dataset with a posterior probability of inclu-
sion of 0 in both BVS analyses and p-values of 0.07
and 0.02 in univariate icensmis and Cox PH analyses,
respectively.
In the dataset of Hispanic American women, a total
of 19 SNPs were identified in the top 10 by at least one
of the three strategies, while simultaneously adjusting for
population stratification (Table 3). SNP rs6547248 was
ranked as the top candidate by the BVSe algorithm and
among the top five SNPs by Cox PH and icensmis. The
host gene CTNNA2 (or Catenin Alpha 2) is a protein
coding gene and may function as a linker between cad-
herin adhesion receptors and the cytoskeleton to regulate
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Table 3 Rankings of individual SNPs in the WHI Clinical Trial and Observational Study SHARe among Hispanic American women in the
WHI (n = 3169). Results from the following analyses are reported: (1) The proposed BVS approach (BVSe); (2) BVS assuming perfect
tests
(
BVSperfect
)
; (3) univariate (SNP by SNP) analysis assuming a Cox PH model; and (4) univariate analysis adjusting for error in
self-report (icensmis). Each analysis simultaneously adjusted for the top two principal components to account for population
stratification. SNPs are ordered from most (rank= 1) to least important (rank > 1000) with regard to their association with time to
incident type 2 diabetes. Ranks > 1000 are denoted by −
BVSe BVSperfect Cox PH icensmis rs Intron Upstream Downstream
Rank Rank Rank Rank Number
1 - 4 2 rs6547248 CTNNA2
2 - 22 28 rs488672 TRIM29 TRIM29, OAF
3 - 19 24 rs1396128 LINC00968 IMPAD1
4 - - - rs2964611 GLRA1, G3BP1
5 - - - rs519206 LYZL1 C10orf126
6 - 3 7 rs6079637 MACROD2
7 - - - rs4778193 OCA2
8 - - - rs1972897 PARD3
9 - - - rs10202023 LOC101927196
10 - 9 8 rs6899814 RNY4 SH3BGRL2, C6orf7
13 - 14 10 rs17253815 GPC6
29 - 5 1 rs17175231 GPC6
86 - 1 3 rs6135332 MACROD2
- - 6 6 rs276637 SHISA9
- - 2 4 rs10242930 TMEM106B, THSD7A
- - 7 5 rs10809502 TYRP1 PTPRD-AS2
- - 10 9 rs1561955 TYRP1 PTPRD-AS2
- - 8 12 rs6079638 MACROD2
- 1 - - rs9610221 HMGXB4 ISX
cell-cell adhesion and differentiation in the nervous sys-
tem [37]. The host gene CTNNA2 was found among 24
novel candidate genes associated with type 2 diabetes risk
in a African American subsample of 973 participants with
type 2 diabetes and 104 healthy control participants in the
GENNID study [38].
SNP rs488672 within host gene TRIM29 was ranked as
second most important by BVSe and among the top 30
SNPs by Cox PH and icensmis. RNA sequence data from
an animal study involving a mouse model of type 2 dia-
betes showed that TRIM29 acts as an E3 ligase that targets
both insulin receptor (IR) and insulin receptor substrate
1 (IRS1) for ubiquitin-dependent degradation, resulting in
insulin resistance [39]. In this study, the authors showed
that TRIM29 levels are ≥ 2.5 fold higher in the kidney
cortex of diabetic mice when compared to wild type mice,
respectively.
SNPs rs6079637 was found among the top 10 SNPs by
all models with the exception of BVSperfect . Similarly, SNP
rs6135332 was found among the top 100 SNPs by BVSe
and among the top five SNPs by Cox PH and icensmis.
Both SNPs are located in the intron of gene MACROD2
and are significantly correlated (p < 0.0001), with R2 =
0.936 and D′ = 1.0 [40]. In a study of 1,100 Han Chi-
nese individuals from 398 families in the Stanford Asian
Pacific Program for Hypertension and Insulin Resistance
study, genetic loci within the MACROD2 gene were asso-
ciated with vascular adhesion protein-1 levels (VAP-1)
in females. VAP-1 is a membrane-bound amine oxidase
highly expressed in mature adipocytes and released into
the circulation. VAP-1 has been strongly implicated in
several pathological processes, including diabetes, inflam-
mation, hypertension, hepatic steatosis and renal diseases,
and is an important disease marker and therapeutic target
[41].
SNP rs6899814was ranked in the top 10 by each strategy
with the exception of BVSperfect , flanked by upstream gene
RNY4 and downstream genes SH3BGRL2 and C6orf7.
Of note, SH3BGRL2 was identified as a gene that is
implicated in type 1 diabetes, type 2 diabetes and gesta-
tional diabetes in a transcriptomemeta-analysis of periph-
eral lymphomononuclear cells [42]. rs6899814 was an
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insignificant predictor of incident type 2 diabetes in the
African American dataset, with a posterior probability
of inclusion of 0 in both BVS analyses and p-values of
0.34 and 0.16 in univariate icensmis and Cox PH analyses,
respectively.
In our independent analyses of African American and
Hispanic American participants in the WHI, we identi-
fied several novel SNPs associated with type 2 diabetes
risk. An overlap in the findings in the two datasets were
two SNPs in the same genomic region that are flanked
upstream by gene LYZL1 and downstream by C10orf126 -
these SNPs were rs17693218 and rs519206 in the datasets
of African American and Hispanic American partici-
pants, respectively. Among the other top ranking SNPs,
there was little overlap between the race/ethnicity groups
(Tables 2-3). These results add to previous observations
in the literature of disease associated genetic loci that are
often not all generalizable across race/ethnicity popula-
tions [43].
Discussion
In this paper, we propose a BVS procedure for variable
selection in high dimensional datasets, in settings where a
time-to-event outcome is observed with error. The mod-
els developed in this paper are motivated by self-reported
outcomes of incident type 2 diabetes collected in the
Women’s Health Initiative, that are subject to misclassifi-
cation. The proposed methods apply to other settings in
which the event of interest is diagnosed using an imper-
fect laboratory-based diagnostic test that is administered
at prescheduled times during follow-up.
We presented results from simulations, considering dif-
ferent data types (GWAS, metabolomics) and a variety of
settings with regard to cumulative incidence of event dur-
ing the study and sensitivity/specificity of the self-report
(or imperfect diagnostic test). When silent outcomes are
ascertained through imperfect self-reports with imperfect
specificity, our proposed algorithm has a significantly bet-
ter performance with regard to variable selection when
compared to the approaches that assume no error in
the outcome ascertainment. In studies where collection
of self-reports or diagnostic test results ceases after the
first positive result, our modified algorithm no longer
performs better than other approaches that ignore the
error in outcomes. We applied the proposed algorithm
to data from the WHI Clinical Trial and Observational
Study SHARe in separate analyses of the data fromAfrican
American and Hispanic American women. We found a
distinct genetic signature associated with type 2 diabetes
risk among the African American and Hispanic American
populations in the WHI, with little overlap in risk alleles
between groups.
The computational burden of BVS approaches can be
considerable. In future work, it would be useful to explore
efficient alternatives to the stochastic search algorithms -
for example, the expectation maximization variable selec-
tion approach [26] could result in significant improvement
in computational efficiency. Other useful extensions of
the BVS procedure could involve incorporating known
biological relationships between predictors, as discussed
in previous work such as [22, 23, 25].
Conclusion
In high dimensional data applications, variable selection
can be negatively impacted when the outcome of interest
is observed with error such as in self-reports. In settings
where the specificity of self-reported outcomes is less
than perfect, a significant degradation in variable selec-
tion accuracy was observed. For this setting, our proposed
algorithm employs a Bayesian variable selection approach
that incorporates a likelihood function that models the
error prone nature of the self-reported outcomes. The
proposed algorithm had significantly better variable selec-
tion performance when compared to similar algorithms
that ignore the error in the outcome. The proposed algo-
rithmwas applied to GWAS data in theWHI Clinical Trial
and Observational Study SHARe to discover novel SNPs
associated with risk of incident type 2 diabetes in African
American and Hispanic American populations.
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